eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2017
vol. 55
 
Share:
Send email
Share:
abstract:
Original paper

Neuropathological characteristics of the brain in two patients with SLC19A3 mutations related to the biotin-thiamine-responsive basal ganglia disease

Maciej Pronicki
,
Dorota Piekutowska-Abramczuk
,
Elżbieta Jurkiewicz
,
Dariusz Rokicki
,
Elżbieta Ciara
,
Joanna Trubicka
,
Katarzyna Iwanicka-Pronicka
,
Magdalena Pajdowska
,
Marek Migdał
,
Wieslawa A. Grajkowska

Folia Neuropathol 2017; 55 (2): 146-153
DOI: https://doi.org/10.5114/fn.2017.68581
Online publish date: 2017/06/30
View full text Get citation
 
PlumX metrics:
Biotin-thiamine-responsive basal ganglia disease is a severe form of a rare neurogenetic disorder caused by pathogenic molecular variants in the thiamine transporter gene. Nowadays, a potentially effective treatment is known, therefore the early diagnosis is mandatory. The aim of the paper was to assess the contribution of neuropathological and magnetic resonance imaging (MRI) studies to a proper diagnosis. We present the brain study of two Polish patients with SLC19A3 mutations, including (1) an infant with an intriguing “walnut” appearance of the brain autopsied many years before the discovery of the SLC19A3 defect, and (2) a one-year-old patient with clinical features of Leigh syndrome. In patient 2, biotin/thiamine responsiveness was not tested at the time of diagnosis and causal treatment started with one-year delay.

The central nervous system lesions found in the patients displayed almost clearly a specific pattern for SLC19A3 defect, as previously proposed in diagnostic criteria. Our study presents a detailed description of neuropathological and MRI findings of both patients.

We confirm that the autopsy and/or MRI of the brain is sufficient to qualify a patient with an unknown neuropathological disorder directly for SLC19A3 mutations testing and a prompt trial of specific treatment.
keywords:

basal ganglia disease, SLC19A3 mutations, MRI, autopsy, neuropathology, thiamine transporter
FEATURED PRODUCTS
BOOKS
• Wprowadzenie do neurologopedii Wydanie II zaktualizowane
EVENTS
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.